MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer
March 14 2016 - 4:00PM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
today announced that Michael E. Castagna, Pharm.D., has joined the
company as its Chief Commercial Officer, effective
immediately. Dr. Castagna will lead commercialization efforts
for Afrezza®, reporting to Matthew Pfeffer, Chief Executive
Officer, and will serve on MannKind’s executive leadership team.
Dr. Castagna has over 20 years of experience in
healthcare, pharmaceutical, biotech and specialty pharmacy
industries. He joins MannKind from Amgen, Inc., where he
spent over three years as Vice President, Global Commercial Lead
for a portfolio of nine biosimilar drugs, and Vice President,
Global Lifecycle Management. Prior to Amgen, Dr. Castagna,
was Executive Director of Bristol-Myers Squibb’s Immunology
franchise, where he served as co-lead to relaunch Orencia IV and
launch Orencia SC, both rheumatoid arthritis drugs. Before
BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and
Division Head for Biopharmaceuticals, North America, where he
established the US Biologics Business Unit and relaunched its lead
product, Omnitrope, a human growth hormone. Prior to Sandoz,
Dr. Castagna held a variety of positions with EMD (Merck), Serono,
Pharmasset and DuPont Pharmaceuticals. Dr. Castagna received
his Bachelors of Science - Pharmacy degree from Philadelphia
College of Pharmacy, his Doctor of Pharmacy from Massachusetts
College of Pharmacy, and his MBA from the Wharton School of
Business at the University of Pennsylvania.
“I’m very pleased to welcome Michael to the
MannKind team in this important new role,” said Matthew Pfeffer,
Chief Executive Officer of MannKind Corporation. “His
extensive pharma background, including driving sales and marketing
for so many new and relaunched products, will be invaluable as we
prepare to reintroduce Afrezza to the market in the coming
months.”
Dr. Castagna said, “I am excited to be joining
MannKind at this critical intersection as we transform our
future. I am enthusiastic about the commercial
opportunity for Afrezza and the potential it has to
help adults with diabetes manage this difficult disease.”
MannKind also announced today that Juergen A.
Martens has resigned as its Chief Operating Officer, effective
March 18, 2016.
Mr. Pfeffer added, “Juergen was instrumental in
building the commercial manufacturing infrastructure that we have
today in Danbury. We thank Juergen for his many contributions
to the company, and we wish him the very best. Operationally,
MannKind’s Chief Technology Officer and Senior Vice President for
Technical Operations, Joseph Kocinsky, will continue his existing
responsibilities for the manufacture of Afrezza.”
About MannKind CorporationMannKind
Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and
development of therapeutic products for patients with diseases such
as diabetes. MannKind maintains a website at
http://www.mannkindcorp.com to which MannKind regularly posts
copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind
issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the
website.
Forward-Looking Statements This
press release contains forward-looking statements that involve
risks and uncertainties, including statements regarding MannKind’s
ability to directly commercialize Afrezza and the commercial
potential of Afrezza. Words such as “believes”,
“anticipates”, “plans”, “expects”, “intend”, “will”, “goal",
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
are based upon the MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
successful transition with Sanofi for the return of Afrezza, the
ability to generate significant product sales for MannKind,
difficulties or delays in obtaining regulatory feedback or
completing and analyzing the results of clinical studies,
MannKind’s ability to manage its existing cash resources or raise
additional cash resources, stock price volatility and other risks
detailed in MannKind’s filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year
ended December 31, 2014 and subsequent periodic reports on Form
10-Q and current reports on Form 8-K. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Company Contact:
Matthew Pfeffer
Chief Executive Officer
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024